en · de · es
sermorelin-notes.peptides6088.com › Guide › Sr9009 Identity And Mechanism — Field Notes

Sr9009 Identity And Mechanism — Field Notes

By Editorial Desk · published 2025-10-18 · last reviewed 2025-11-13 · Guide

REV-ERB agonist raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

Reviewed 2025-11-13. Anything still debated is marked as such rather than presented as settled.

SR9009 Identity and Mechanism

SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.

REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.

Background and Pharmacological Mechanism

Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.

SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.

Sr9009 at a glance

PropertyValueNotes
Common nameSR9009Also marketed informally as Stenabolic
Chemical classSynthetic REV-ERB agonistBinds REV-ERBα and REV-ERBβ
Molecular formulaC24H30ClN3O4SApproximate molecular weight 492 g/mol
CAS Registry Number1379686-30-2Identifier for the parent compound
Regulatory statusNot approved for human useProhibited in sport by WADA

Background and Receptor Mechanism

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.

At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.

Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.

Related pages on this site

Background and Receptor Pharmacology

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.

Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.

Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.

Background from the literature

=== Neuroanatomy === Nociceptin controls a wide range of biological functions ranging from nociception to food intake, from memory processes to cardiovascular and renal functions, from spontaneous locomotor activity to gastrointestinal motility, from anxiety to the control of neurotransmitter release at peripheral and central sites.

=== Dairy products === Chinese in earlier dynasties evidently drank milk and ate dairy products, although not necessarily from cows, but kumis (fermented mare's milk) or goat's milk. Kumis was historically consumed in northern China. China also has a number of native cheeses, mostly of the non-Han culinary traditions. Nguri, however, is a traditional cheese of southern China — mainly Fujian, Guangdong, and the area around Shanghai — historically consumed by the Han. It is a buffalo-milk cheese traditionally served in small amounts on congee. China's non-Han cheeses include Uyghur kurut, Mongolian byaslag and eezgii, Tibetian chhurpi, and Yi rushan and rubing.

1 On 3 March 2001, Minister for Planning and Infrastructure Alannah MacTiernan, whose portfolio included road safety, lost her licence after being booked for driving at 98 km/h in a 60 km/h zone near Pinjarra. On 9 March 2001, Premier Gallop appointed Minister for Police Michelle Roberts as Minister assisting the Minister for Planning and Infrastructure with respect to Road Safety, meaning that Roberts would chair the Ministerial Council on Road Safety and be responsible for three Acts of Parliament. 2 The parliamentary secretaries were not appointed at the same time as the rest of the Ministry. A separate announcement was made on 23 March 2001 confirming their appointments. 3 On 27 June 2003, a Cabinet reshuffle removed Health from Bob Kucera and Housing and Works from Tom Stephens, reallocating the portfolios to Jim McGinty and Nick Griffiths respectively. The membership of the Cabinet remained unchanged. 4 On 16 September 2004, Tom Stephens MLC resigned from the Ministry and from Parliament in order to contest the seat of Kalgoorlie at the October 2004 federal election. Kim Chance adopted the portfolios before they were reassigned to Ljiljanna Ravlich, who was promoted from parliamentary secretary to Minister on 21 September 2004.

Although some biogeochemists such as Rogers et al. (2012) have identified sites of hydrothermal vents, the locations of known hydrothermal vent formations in deep sea systems is not well understood. The ocean floor is not well explored, with less than 1% being well known. Most of the hydrothermal vents scientists are currently aware of form along mid ocean ridges. The location of these systems is important to understanding their formation, as most accepted theories revolve around seismic activity, particularly near volcanic regions. Seismic activity during Paleocene and Eocene continental rifting led to an eruption of gases, liquids, and sediments from the Earth's core. This intrusive event created large craters sitting on top of sills. Sills are layers of igneous rock where magma intrudes between existing layers of stratified rock. These large craters on the seafloor are collections of hydrothermal vents. Distinct features of these vents include inward-dipped sedimentary strata, and sandstone dykes, pipes, and breccias. These features are categorized as subvolcanic intrusions, which lead to hydrothermal activity. A study used 2D seismic reflection data, to characterize the structures of these systems, which are sunken in craters with a funneled side profile. These structures are often referred to as chimneys which form over the surface of the vents. The oceanic crust and the seawater interact to form these systems, and alter the local chemistry and form deposits that are rich in varying metals.

Sources: en.wikipedia.org

Further detail

After graduating in 1953 from the University of Malaya, Mahathir began his housemanship at Penang General Hospital. In 1954, he was sent to Alor Setar General Hospital before being posted to government clinics in Langkawi, Jitra, and Perlis. During his time in Langkawi in 1955, Mahathir was the island's first stationed doctor, witnessing its underdeveloped state—a memory that later influenced his efforts to transform it into a major tourist destination when he became prime minister. Reflecting on his early career, Mahathir said he prioritised work over salary, starting with MYR 400.00 as a medical officer before a promotion raised it to MYR 770.00. He then resigned to open his private practice, named "Maha Klinik" (Maha Clinic), while his wife worked as a government doctor for 25 years. Maha Klinik was the first privately owned clinic established by a Malay in Malaysia. Mahathir acquired the reputation of being a caring doctor, willing to make house calls at any hour, trudging across rice fields in the dark to treat patients. If they could not afford his fee, they settled by installments or paid what they had. He was the town's first Malay physician and a successful one. He built a large house and employed a Chinese man to chauffeur him in his Pontiac Catalina (most chauffeurs at the time were Malay). Mahathir and Siti Hasmah were also involved in welfare and public health activities.

==== Tulips ==== Tulips have been cultivated since at least the tenth century in Persia. Tulip production has two main markets: cut flowers and bulbs. The latter are used, in turn, to meet the demand for bulbs for parks, gardens, and home use and, secondly, to provide the necessary bulbs for cut flower production. International trade in cut flowers has an approximate total value of 11 billion euros, which provides an indication of the economic importance of this activity. The main producer of tulip bulbs is the Netherlands, a country that accounts for 87% of the global cultivated area, with approximately 12,000 hectares. Other leading producers include Japan, France and Poland. Approximately ten other countries produce commercial tulips, largely for the domestic market. By contrast, the Netherlands is the leading international producer, to the extent of 4 billion bulbs per annum. Of these, 53% are used for the cut flower market and the remainder for the dry bulb market. Of the cut flowers, 57% are used for the domestic market in the Netherlands and the remainder exported. Original Tulipa species can be obtained for ornamental purposes, such as T. tarda and T. turkestanica. These are referred to as species, or botanical, tulips, and tend to be smaller plants but better at naturalising than the cultivated forms. Breeding programs have produced a wide range of tulip types, enabling blooming through a much longer season by creating early, mid- and late spring varieties.

facilitated diffusion A type of passive transport by which substances are conveyed across membranes more quickly than would be possible by ordinary passive diffusion alone, generally because proteins embedded within the membrane act as shuttles or pores, being arranged in such a way as to provide a hydrophilic environment that is favorable for the movement of small polar molecules, which would otherwise be repulsed by the hydrophobic interior of the lipid bilayer.

Sources: en.wikipedia.org

Background from the literature

Sugar cane accounted for around 21% of the global crop production over the 2000–2021 period. The Americas was the leading region in the production of sugar cane (52% of the world total). Global production of sugarcane in 2022 was 1.9 billion tonnes, with Brazil producing 38% of the world total and India 23% (table). Sugarcane is any of several species, or their hybrids, of giant grasses in the genus Saccharum in the family Poaceae. They have been cultivated in tropical climates in the Indian subcontinent and Southeast Asia over centuries for the sucrose found in their stems.

23 September – Media outlets, including BBC News, report that a number of firearms officers have stepped back from their role within the Metropolitan Police after a colleague was charged with murder over the shooting of Chris Kaba. Former prime minister Boris Johnson warns present prime minister Rishi Sunak against building what he describes as a "mutilated" version of HS2 following reports that the northern leg of the route from Birmingham to Manchester could be scrapped amid concerns over spiralling costs. 24 September – The Ministry of Defence is offering the Metropolitan Police armed soldiers to support its officers after several firearms officers handed in their weapons. Greater Manchester becomes the first area of England to reverse bus deregulation with the launch of its Bee Network, whereby bus services are franchised by the local authority to bus companies. 25 September – NHS England announces that more than one million appointments and treatments have been lost due to strike action by NHS staff. Mayor of Greater Manchester Andy Burnham says that scrapping the HS2 rail link between Birmingham and Manchester risks "ripping the heart" out of plans to improve rail services across northern England. 27 September – Comer Homes Group is ordered to demolish two tower blocks it built as part of the Mast Quay Phase II complex after Greenwich Borough Council planners determined the blocks differed significantly from the original plans that were submitted and approved in 2012.

The POI is isolated, typically by SDS-PAGE or chromatography. The isolated POI may be chemically modified to stabilise Cysteine residues (e.g. S-amidomethylation or S-carboxymethylation). The POI is digested with a specific protease to generate peptides. Trypsin, which cleaves selectively on the C-terminal side of Lysine or Arginine residues, is the most commonly used protease. Its advantages include i) the frequency of Lys and Arg residues in proteins, ii) the high specificity of the enzyme, iii) the stability of the enzyme and iv) the suitability of tryptic peptides for mass spectrometry. The peptides may be desalted to remove ionizable contaminants and subjected to MALDI-TOF mass spectrometry. Direct measurement of the masses of the peptides may provide sufficient information to identify the protein (see Peptide mass fingerprinting) but further fragmentation of the peptides inside the mass spectrometer is often used to gain information about the peptides’ sequences. Alternatively, peptides may be desalted and separated by reversed phase HPLC and introduced into a mass spectrometer via an ESI source. LC-ESI-MS may provide more information than MALDI-MS for protein identification but uses more instrument time. Depending on the type of mass spectrometer, fragmentation of peptide ions may occur via a variety of mechanisms such as collision-induced dissociation (CID) or post-source decay (PSD). In each case, the pattern of fragment ions of a peptide provides information about its sequence.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.

Is SR9009 approved for human use?

No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.

Why is SR9009 banned in sport?

The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.

What is SR9009?

It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.

Network